irinotecan


Also found in: Acronyms, Wikipedia.

irinotecan

/iri·no·te·can/ (i″rĭ-no-te´kan) a DNA topoisomerase inhibitor used as the hydrochloride salt as an antineoplastic in the treatment of colorectal carcinoma.

irinotecan

an antineoplastic hormone.
indication It is used to treat metastatic carcinoma of the colon or rectum.
contraindications Pregnancy and known hypersensitivity to this drug prohibit its use.
adverse effects Life-threatening effects include leukopenia, anemia, and neutropenia. Other adverse effects include fever, headache, chills, dizziness, diarrhea, nausea, vomiting, anorexia, constipation, cramps, flatus, stomatitis, dyspepsia, site irritation, rash, sweating, dyspnea, increased cough, rhinitis, vasodilation, edema, asthenia, and weight loss.

irinotecan

A topoisomerase-1 inhibitor and semisynthetic analogue of the natural alkaloid camptothecin, which is activated by hydrolysis in vivo to an active metabolit, SN-38, and inactivated by glucuronidation with uridine diphosphate glucoronosyltransferase 1A1 (UGT1A1). It was FDA-approved for managing colorectal carcinoma in 1994. 

Adverse effects
Severe diarrhoea, possibly leading to dehydration, requiring aggressive antidiarrhoeal management with loperamide or Lomotil; immunosuppression with severe neutropaenia; functional overdose in patients who under-express UGT1A1 and cannot clear irinotecan as quickly (e.g., those with Gilbert syndrome as normal patients).

irinotecan

An anticancer drug used to treat widespread secondary cancer of the colon or rectum. A brand name is Campto.
References in periodicals archive ?
In the CApecitabine IRinotecan Oxaliplatin (CAIRO)2 study, the effect of adding cetuximab to capecitabine, oxaliplatin and bevacizumab (CapOx-bev) in the first-line treatment of advanced CRC [33] has been evaluated.
The Erbitux data included a randomized controlled study of 329 patients with metastatic colorectal cancer that expressed EGFR; they received Erbitux alone or in combination with irinotecan.
Specifically, the presence of DNA methylation for a panel of 22 genes was evaluated on primary tumours of 185 patients with metastatic CRC treated with first-line capecitabine (CAP, n=90) or a combination of capecitabine and irinotecan (CAPIRI, n=95) in a Phase III study, dubbed CAIRO.
This report and further publications appeared after the newer cytotoxic drugs irinotecan [2] and oxaliplatin [3,4] were introduced as treatment options for colorectal cancer.
The 23% tumor response rate (complete plus partial response) in 218 patients randomized to cetuximab (Erbitux) plus irinotecan was significantly greater than that the 11% rate in 111 patients who received cetuximab alone (N.
Specialist pharmaceutical company Sagent Pharmaceuticals Inc (Nasdaq:SGNT) said on Thursday that it has introduced its Irinotecan Injection in two latex free, preservative free single dose vials.
Cetuximab was administered with irinotecan (90-minute infusion of 180 mg/[m.
The addition of bevacizumab to irinotecan, fluorouracil, and leucovorin (IFL) increased the overall median survival of patients who were receiving primary treatment for metastatic colorectal cancer to 20.
HA-Irinotecan employs the company's HyACT platform that targets the widely used chemotherapy drug irinotecan directly to tumour cells.
The progress began when irinotecan and oxaliplatin became available.